Juul SE, Vu PT, Comstock BA, et al. - This randomized phase 3 clinical trial was undertaken to determine if high-dose erythropoietin given within 24 hours of birth through postmenstrual age of 32 completed weeks will reduce the need for blood transfusions. This investigation was carried out at 19 sites consisting of 30 neonatal intensive care units across the United States. In total, 936 patients (488 male [52.1%]) were involved, with a mean (SD) gestational age of 25.6 (1.2) weeks and mean (SD) birth weight of 799 (189) g. According to results, erythropoietin given according to protocol significantly reduced the number of transfusions, the cumulative volume of transfusions, and the unique donor exposures. Such results indicate that high-dose erythropoietin reduces transfusion demands in infants with a gestational age of 24 to 27 weeks and raises the number who remain transfusion free.